Use of NK-1 receptor antagonists for treating stress disorders
US6087348A · kind A · utility
0Cited by
10References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 9, 1999 |
| Grant date | Jul 11, 2000 |
| Priority date | — |
| Expiry date | Jun 9, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/675
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides the use of an orally active, long acting, CNS-penetrant NK-1 receptor antagonist for the manufacture of a medicament adapted for oral administration for the treatment or prevention of stress disorders without concomitant therapy with other anti-stress agents, methods of treatment using such a NK-1 receptor antagonist and pharmaceutical compositions comprising it.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.